Comparing Avinger (AVGR) & Accuray (ARAY)

Avinger (NASDAQ: AVGR) and Accuray (NASDAQ:ARAY) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.

Insider & Institutional Ownership

How to Become a New Pot Stock Millionaire

72.9% of Avinger shares are owned by institutional investors. Comparatively, 82.0% of Accuray shares are owned by institutional investors. 17.0% of Avinger shares are owned by insiders. Comparatively, 3.9% of Accuray shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Avinger and Accuray’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Avinger -490.56% N/A -157.92%
Accuray -6.09% -44.66% -5.20%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Avinger and Accuray, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avinger 0 3 2 0 2.40
Accuray 1 2 3 0 2.33

Accuray has a consensus price target of $7.40, suggesting a potential upside of 57.45%. Given Accuray’s higher probable upside, analysts plainly believe Accuray is more favorable than Avinger.

Earnings and Valuation

This table compares Avinger and Accuray’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Avinger $9.93 million 0.52 -$48.73 million ($70.07) -0.02
Accuray $383.41 million 1.05 -$29.57 million ($0.36) -13.06

Accuray has higher revenue and earnings than Avinger. Accuray is trading at a lower price-to-earnings ratio than Avinger, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Avinger has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Comparatively, Accuray has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500.

Summary

Accuray beats Avinger on 10 of the 13 factors compared between the two stocks.

About Avinger

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat, and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. The company sells and markets its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was founded in 2007 and is headquartered in Redwood City, California.

About Accuray

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. The CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. It also offers the TomoTherapy System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. The company markets its products in the United States directly, as well as through a sales agent and group purchasing organizations; and directly and through distributors and sales agents in Europe, Japan and other countries of Asia, South America, and internationally to hospitals and stand-alone treatment facilities. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California.

Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

BNP Paribas Reiterates CHF 74 Price Target for Nestle
BNP Paribas Reiterates CHF 74 Price Target for Nestle
Roche  Given a CHF 230 Price Target at Morgan Stanley
Roche Given a CHF 230 Price Target at Morgan Stanley
Vermilion Energy  Price Target Raised to C$60.00 at Scotiabank
Vermilion Energy Price Target Raised to C$60.00 at Scotiabank
Spartan Energy  Downgraded by Raymond James to “Market Perform”
Spartan Energy Downgraded by Raymond James to “Market Perform”
Critical Survey: Match Group  versus Its Rivals
Critical Survey: Match Group versus Its Rivals
Financial Contrast: RPM International  and AkzoNobel
Financial Contrast: RPM International and AkzoNobel


Leave a Reply

© 2006-2018 Ticker Report. Google+.